Report Scope:
The scope of this study encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanisms of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI), and amyloid-beta (Aβ) vaccines. Drugs are also segmented by the stage of Alzheimer’s disease they treat, i.e., mild to moderate, severe, and prodromal.
The publisher analyzed each market and its applications, regulatory environment, assistive technologies, market projections, and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features, and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China, and India. These markets are grouped as North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
The Report Includes:
- 27 tables
- An overview of the global market for Alzheimer's disease (AD) therapeutics and diagnostics
- Estimation of the market size and analyses of global market trends with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- A detailed description of Alzheimer's disease and discussion on disease-related events, etiology, and epidemiology covering prevalence and incidence rates
- Identification of diagnostic tools and equipment; evaluation of important scientific and technological frameworks; and coverage of developments in the global market for Alzheimer's disease therapeutics and diagnostics.
- Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease as well as highlights of the promising new drug candidates and diagnostic imaging agents
- Market share analysis of Alzheimer's disease therapeutics and diagnostics, by the mechanism of action, disease stage, and major geographical regions covering North America, Europe, APAC, and Rest of the World
- Detailed analysis of the current market trends, market forecast, drivers, challenges, and opportunities affecting market growth and discussion on regulatory and competitive elements that are affecting the future marketplace
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of major market players, including AbbVie, AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc., Novartis, and Sanofi
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing this Study
- Scope of Report
- Information Sources
- Methodology
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
- Alzheimer's Disease: Definition and Market Structure
- Alzheimer's Disease Pathophysiology
- AD and Amyloid Cascade
- AD and Tauopathy
- AD and Neurotransmitter Systems
- Alzheimer's Disease Etiology
- Genetic Factors
- Non-Genetic Factors
- Alzheimer's Disease Epidemiology
- Age of Onset
- Incidence, Prevalence and Mortality
- Stages and Severity of AD
- Comorbidities
- Diagnosis and Treatment of Alzheimer's
- Diagnosis of Alzheimer's
- Companion Imaging Diagnostics for AS
- CIDX Technologies for Amyloid Visualization
- CIDX Technologies for TAU-NFT Visualization
- Comparative Analysis of Tau Tracers in Development
- CIDX Technologies: Aβ vs. Tau Imaging Technologies
- Concluding Remarks
- Pharmaceutical Treatment of AD
Chapter 4 Regulatory Structure
- U.S.
- Accelerated Approvals
- Fast Track Designation
- Breakthrough Therapy Designation
- Priority Review
- Controlled Substances Act
- Special Protocol Assessments
- New Surveillance and Safety Requirements
- Canada
- Mexico
- Europe
- Asia-Pacific
- Rest of the World
- Reimbursement Landscape
Chapter 5 Market Dynamics
- Market Drivers
- Use of Biomarkers in Diagnosis and Drug Development
- Large Number of Drugs in the Pipeline
- Market Restraints
- Patent Expirations of Branded Drugs and Emergence of Generics
- High Failure Rate in Drug Development
- High Cost of Drug Development
Chapter 6 Global Markets for Alzheimer's Disease Therapeutics
- Market Overview
- Global Market for Alzheimer's Drugs by Mechanism of Action
- Acetylcholinesterase Inhibitors (AChEIs)
- NMDA Drugs
- Global Market for Branded/Generic AD Therapeutics by Type
- Global Market for AD Therapeutics by Stage of AD
Chapter 7 Market Breakdown by Region
- Global Market for Alzheimer's Drugs by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Industry Structure
- Impact of Generic AD Therapeutics
Chapter 8 Pipeline Analysis
- Overview of the Drug Development Process
- Phase III
- Phase II
- Phase I
- Trial Sponsors
Chapter 9 Company Profiles
- Abbvie
- Acadia Pharmaceuticals Inc.
- Alembic Pharmaceuticals Ltd.
- Alexza Pharmaceuticals
- Alkermes Plc
- Allergan Plc
- Apotex Inc.
- Astrazeneca Plc
- Aurobindo Pharma
- Avanir Pharmaceuticals Inc.
- Boehringer Ingelheim
- Bristol-Myers Squibb Co.
- Biogen
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly And Co.
- Eisai Co., Ltd.
- F. Hoffmann-La Roche Ag
- Glaxosmithkline Plc
- Gedeon Richter Plc
- Immunocellular Therapeutics Ltd.
- Johnson & Johnson
- Lannett Co., Inc.
- H. Lundbeck A/S
- Lupin Ltd.
- Mallinckrodt
- Merck & Co.
- Mylan Nv
- Nextsource Biotechnology Llc
- Novartis Ag
- Otsuka Holdings Co., Ltd.
- Pfizer Inc.
- Sanofi
- Sumitomo Dainippon Pharma Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- UCB SA
Chapter 10 Appendix: Acronyms
List of Tables
Summary Table: Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 1: Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Table 2: Pharmacological Treatment of BPSD of Alzheimer's
Table 3: Computerized Screening Tests Used in Detecting Cognitive Impairment
Table 4: Brain Imaging Technologies and Application in the Alzheimer's Context
Table 5: Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 6: Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
Table 7: Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
Table 8: Global Market for Alzheimer's Drugs, by Type, Through 2025
Table 9: Global Market for AD Therapeutics, by Disease Stage, Through 2025
Table 10: Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
Table 11: Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
Table 12: Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 13: North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 14: North American Market for Alzheimer's Drugs, by Country, Through 2025
Table 15: North American Market for Alzheimer's Drugs, by Type, Through 2025
Table 16: European Market for Alzheimer's Drugs, by Country, Through 2025
Table 17: European Market for Alzheimer's Drugs, by Type, Through 2025
Table 18: European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 19: Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
Table 20: Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 21: Global Ranking of Leading Players in Alzheimer's Disease Drugs
Table 22: Agents in Phase III of Alzheimer's Disease Drug Development
Table 23: Agents in Phase II of Alzheimer's Disease Drug Development
Table 24: Agents in Phase I of Alzheimer's Disease Drug Development
Table 25: Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
Table 26: Acronyms Used in This Report
List of Figures
Summary Figure: Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 1: Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Figure 2: Pharmaceutical Regulatory Pathways in the U.S. and Europe
Figure 3: Global Market for Alzheimer's AChEIs Drugs, 2019-2025
Figure 4: Global Market for Alzheimer's NMDA Drugs, 2019-2025
Figure 5: Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 6: North American Market for Alzheimer's Drugs, 2019-2025
Figure 7: European Market for Alzheimer's Drugs, 2019-2025
Figure 8: Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
Figure 9: South American Market for Alzheimer's Drugs, 2019-2025
Figure 10: Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025
Samples
LOADING...
Executive Summary
The increased government funding in neurology research and an ever-growing demand for research focused on drug discovery for the development of novel therapies in neurological disorders are driving the growth of the market.
Reasons for Doing This Study:
Alzheimer’s disease cannot be prevented, cured, or slowed, and it is a rapidly growing and serious health problem, affecting more than 17 million worldwide. Therapies for AD provide temporary and modest improvements in the well-being of individuals, but none of the approved drugs can modify the course of the disease progression. The immense size of the affected population and lack of appropriate and effective treatment offers a tremendous commercial opportunity for the makers of AD drugs and diagnostics.
The understanding of the underlying reasons and mechanisms involved in AD is very limited. Drug developers have continually failed to demonstrate meaningful clinical benefits of treatment for a myriad of investigational compounds due to stringent regulations. High drug attrition rates and long drug approval times have driven pharmaceutical companies and technology ventures closer to each other for collaborations. Specifically, diagnostic technology companies are rigorously trying to bring about effective biomarker technologies to assist and enhance the drug development process for prospective drug candidates. Regulatory bodies are highly supportive of the use of diagnostic technologies in order to improve drug attrition rates.
Despite the recurring failures in the development of novel therapies for AD, the global markets are demanding new and more effective disease attenuating treatments, with first-in-class approvals. This expectation and the increasing incidence of AD associated with the aging population are driving the market.
Companies Mentioned
- Abbvie
- Acadia Pharmaceuticals Inc.
- Alembic Pharmaceuticals Ltd.
- Alexza Pharmaceuticals
- Alkermes Plc
- Allergan Plc
- Apotex Inc.
- Astrazeneca Plc
- Aurobindo Pharma
- Avanir Pharmaceuticals Inc.
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eisai Co., Ltd.
- Eli Lilly And Co.
- F. Hoffmann-La Roche Ag
- Gedeon Richter Plc
- Glaxosmithkline Plc
- H. Lundbeck A/S
- Immunocellular Therapeutics Ltd.
- Johnson & Johnson
- Lannett Co., Inc.
- Lupin Ltd.
- Mallinckrodt
- Merck & Co.
- Mylan Nv
- Nextsource Biotechnology Llc
- Novartis Ag
- Otsuka Holdings Co., Ltd.
- Pfizer Inc.
- Sanofi
- Sumitomo Dainippon Pharma Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- UCB SA
![Global Alzheimer's Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Forecast 2024-2030 - Product Image](http://www.researchandmarkets.com/product_images/11393/11393578_60px_jpg/global_alzheimers_therapeutics_market.jpg)
